Vor Biopharma reprices employee stock options to $8.18; CEO gets 4.16M options repriced

Vor Biopharma Inc.

Board reduced exercise price of ~5.2M underwater options to $8.18, the Dec 5, 2025 closing price.
Repriced options originally ranged from $17.80 to $47.60; CEO Jean-Paul Kress repriced 4,164,831 options.
Retention period ends Dec 5, 2027; options exercised earlier retain original exercise price.
CFO Sandy Mahatme received option for 1,388,274 shares at $17.80, reducing to $8.18 after retention period.
Repricing aims to retain employees and avoid dilution from new equity grants or cash comp.

item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.